Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial
Jean-Marc Classe, Pierre Méeus, Delphine Hudry, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 12, pp. 1551-1562
Closed Access | Times Cited: 18

Showing 18 citing articles:

Cytoreductive Surgery Plus HIPEC in Recurrent or Newly Diagnosed Advanced Epithelial Ovarian Cancer: a Meta-analysis
Cristina Taliento, Stefano Restaino, Martina Arcieri, et al.
Annals of Surgical Oncology (2025)
Open Access | Times Cited: 2
Turning Up the Heat: Weighing the Role of HIPEC in Secondary Cytoreduction for Ovarian Cancer
Mayara Lopes Araújo, Mariana Carvalho Gouveia, Rafaela Melo Campos Borges, et al.
International Journal of Gynecological Cancer (2025) Vol. 35, Iss. 2, pp. 101621-101621
Closed Access
Complications in CRS and HIPEC: From Reduction to Effective Management
Zakaria El mouatassim, Amine Souadka
Journal of Surgical Oncology (2025)
Closed Access
CHIPOR, HORSE, and beyond: unraveling the role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer
Myong Cheol Lim
Journal of Gynecologic Oncology (2025) Vol. 36, Iss. 1
Open Access
CHIPOR: gaps in recurrent ovarian cancer management
Atahan Toyran, Hamdullah Sözen, Yağmur Minareci, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 2, pp. e76-e76
Closed Access
Management of Recurrence in Ovarian Cancer—The Role of Surgery and HIPEC with Relevance to BRCA Testing in a PARPi Landscape
Method A. Duchon, Raj Naik, Fabrice Lécuru, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 646-646
Open Access
ASO Author Reflections: HIPEC’s Impact on Advanced Ovarian Cancer: A Meta-analysis
Cristina Taliento, Martina Arcieri, Stefano Restaino, et al.
Annals of Surgical Oncology (2025)
Closed Access
More evidence on benefits of HIPEC for recurrent ovarian cancer
Mary Beth Nierengarten
Cancer (2025) Vol. 131, Iss. 5
Open Access
Evaluating the Impact of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) on Interval and Secondary Debulking in Ovarian Cancer: A Systematic Review
Dimitrios Tsolakidis, Dimitrios Kyziridis, Theodoros Panoskaltsis, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 904-904
Open Access
Reflections on the HORSE Trial: Hyperthermic Intraperitoneal Chemotherapy, BRCA Status, and Clinical Implications
Hamdullah Sözen, Yağmur Minareci, Atahan Toyran, et al.
Journal of Clinical Oncology (2025)
Closed Access
Reply to: Reflections on the HORSE Trial: Hyperthermic Intraperitoneal Chemotherapy, BRCA Status, and Clinical Implications
Gini F. Fleming
Journal of Clinical Oncology (2025)
Closed Access
Reply to: Reflections on the HORSE Trial: Hyperthermic Intraperitoneal Chemotherapy, BRCA Status, and Clinical Implications
Anna Fagotti, Rita Trozzi, Diana Giannarelli, et al.
Journal of Clinical Oncology (2025)
Closed Access
HIPEC in recurrent ovarian cancer: flogging a tired HORSE?
Aditi Bhatt, Mufaddal Kazi, Geetu Bhandoria, et al.
Journal of Gynecologic Oncology (2025) Vol. 36
Open Access
Expert commentary on HORSE/MITO18 and CHIPOR
Edin Karabeg, Philipp Harter
Journal of Gynecologic Oncology (2025) Vol. 36
Open Access
EXTENding the timing for Secondary cytoreductive surgery after second line chemotherapy In relapsed OvariaN cancer: the EXTENSION study.
Carmine Conte, Luigi Congedo, Cláudia Marchetti, et al.
International Journal of Gynecological Cancer (2025), pp. 101824-101824
Closed Access
Feasibility of a Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Program for Gastrointestinal and Gynecological Cancer Care in Newfoundland and Labrador
Kala Hickey, Stephanie Gill, Zoë Breen, et al.
Onco (2025) Vol. 5, Iss. 2, pp. 16-16
Open Access
Meta-analysis on Cytoreductive Surgery Plus HIPEC in Recurrent or Newly Diagnosed Advanced Epithelial Ovarian Cancer: Food for Thoughts in a Period of Novelties
Valentina Ghirardi, Giovanni Scambia, Anna Fagotti, et al.
Annals of Surgical Oncology (2025)
Closed Access
The INDEPSO-ISPSM Consensus on Peritoneal Malignancies—Management of Advanced Epithelial Ovarian Cancer
Neha Kumar, Aditi Bhatt, Snita Sinukumar, et al.
Indian Journal of Surgical Oncology (2025)
Closed Access
Secondary cytoreductive surgery with HIPEC: a promising therapeutic option for recurrent ovarian cancer
Taymaa May
The Lancet Oncology (2024)
Closed Access
HIPEC is effective in patients undergoing cytoreduction for recurrent ovarian cancer
Peter Sidaway
Nature Reviews Clinical Oncology (2024)
Closed Access
The CHIPOR trial- Sufficient evidence to use HIPEC in routine care for recurrent ovarian cancer?
Aditi Bhatt, Mufaddal Kazi, Amine Souadka, et al.
International Journal of Gynecological Cancer (2024) Vol. 35, Iss. 1, pp. 100040-100040
Closed Access
Page 1

Scroll to top